Latest Breaking News On - Dafnad gladman - Page 2 : comparemela.com

In psoriatic arthritis patients with axial involvement, researchers saw sustained improvement with guselkumab through 100 weeks on all outcomes employed to evaluate change in axial symptoms.

Guselkumab tremfyaWalterp maksymowychDafnad gladmanUniversity of torontoSpondyloarthritis research consortium of canadaUniversity of albertaCanadian rheumatology associationDrug administrationAmerican college of rheumatologyCanadian rheumatologyAmerican collegeAnkylosing spondylitis disease activity scoreSpondyloarthritis research consortiumPsoriatic arthritisAnkylosing spondylitis bechterews diseaseBiologic therapy